Melastatin expression and prognosis in cutaneous malignant melanoma

Journal of Clinical Oncology

Volumn 19, Issue 2, 2001, Pages 568-576

  Duncan, L M ^a   Deeds, J ^a   Cronin, F E ^a   Donovan, M ^a   Sober, A J ^a   Kauffman, M ^a   McCarthy, J J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELASTATIN; MESSENGER RNA; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; METASTASIS; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; SKIN CANCER; THICKNESS;

EID: 0035863283     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.2.568     Document Type: Article

References (39)

1. Malignant melanoma: Perspectives on incidence and its effects on awareness, diagnosis, and treatment
2. The incidence of malignant melanoma in the United States: Issues as we approach the 21st century
3. Cutaneous melanoma: Prognosis and treatment results worldwide
4. Changing trends in the clinical and pathologic features of melanoma
5. Cancer statistics: 1996
6. Vaccine therapy for malignant melanoma
7. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis
8. Model predicting survival in stage I melanoma based on tumor progression
9. Tumor progression, early diagnosis and prognosis of melanoma
10. Prognostic indicators in melanoma
11. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma
12. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
13. Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters
14. Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma?
15. Beta3 integrin expression in melanoma predicts subsequent metastasis
16. Localization of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor mRNAs in rat brain
17. Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development
18. Patterns of melastatin mRNA expression in melanocytic tumors
19. Chromosomal localization and genomic characterization of the mouse melastatin gene (MLSN-1)
20. Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression
21. Molecular cloning of a novel putative Ca2+ channel protein (TRPC7) highly expressed in brain
22. in in human melanoma cells with different metastatic potential
23. Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, Spirulina platensis
24. CREB and its associated proteins act as survival factors for human melanoma cells
25. Clotrimazole inhibits cell proliferation in vitro and in vivo
26. Cell-permeant caged InsP3 ester shows that Ca2+ spike frequency can optimize gene expression
27. The prognostic significance of ulceration of cutaneous melanoma
28. Prognostic factors in malignant melanoma
29. A prognostic model for predicting 10-year survival in patients with primary melanoma
30. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study
31. Prognostic factors in cutaneous malignant melanoma in stage I: A clinical, morphological and multivariate analysis
32. Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients
33. Outcome of patients with melanoma and histologically negative sentinel lymph nodes
34. Technical details of intraoperative lymphatic mapping for early stage melanoma
35. Detection of microscopic melanoma metastases in sentinel lymph nodes
36. The role of sentinel lymph node mapping for melanoma
37. Sentinel lymph node evaluation in melanoma
38. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
39. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases: French Cooperative Group on Melanoma